TransCode Therapeutics has strengthened its scientific leadership by appointing Dr. Phillip D. Zamore to its Scientific Advisory Board. Dr. Zamore, a distinguished researcher in RNA interference (RNAi) and co-founder of Alnylam Pharmaceuticals, brings extensive expertise in RNA biology and gene silencing mechanisms to the oncology-focused company.
As Chair of the RNA Therapeutics Institute at UMass Chan Medical School, Zamore's election to the National Academy of Sciences underscores his significant contributions to the field. His appointment signals a strategic enhancement to TransCode's RNA-targeted cancer therapy programs, potentially accelerating the development of innovative treatment approaches.
TransCode is currently developing TTX-MC138, a therapeutic candidate targeting metastatic tumors that overexpress microRNA-10b. The company's proprietary TTX nanoparticle platform aims to overcome traditional challenges in RNA delivery, potentially unlocking new genetic targets for cancer treatment.
Zamore's involvement could provide critical insights into advancing TransCode's research, particularly in developing first-in-class RNA therapeutic candidates. His expertise may help refine the company's approach to targeting complex genetic mechanisms underlying metastatic diseases.
